These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7507054)

  • 1. Pathophysiology of benign prostatic hyperplasia.
    Algaba F
    Eur Urol; 1994; 25 Suppl 1():3-5. PubMed ID: 7507054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer.
    Barclay WW; Woodruff RD; Hall MC; Cramer SD
    Endocrinology; 2005 Jan; 146(1):13-8. PubMed ID: 15471963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture.
    Boudon C; Rodier G; Lechevallier E; Mottet N; Barenton B; Sultan C
    J Clin Endocrinol Metab; 1996 Feb; 81(2):612-7. PubMed ID: 8636277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal nodules in benign prostatic hyperplasia.
    Bierhoff E; Vogel J; Benz M; Giefer T; Wernert N; Pfeifer U
    Eur Urol; 1996; 29(3):345-54. PubMed ID: 8740022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign prostatic hyperplasia: age-related tissue-remodeling.
    Untergasser G; Madersbacher S; Berger P
    Exp Gerontol; 2005 Mar; 40(3):121-8. PubMed ID: 15763388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and experimental studies of benign prostatic hyperplasia.
    Coffey DS; Walsh PC
    Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia.
    Giri D; Ittmann M
    Am J Pathol; 2001 Jul; 159(1):139-47. PubMed ID: 11438462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications.
    Sun F; Crisóstomo V; Báez-Díaz C; Sánchez FM
    Cardiovasc Intervent Radiol; 2016 Jan; 39(1):1-7. PubMed ID: 26581418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
    Berger AP; Horninger W; Bektic J; Pelzer A; Spranger R; Bartsch G; Frauscher F
    BJU Int; 2006 Sep; 98(3):587-90. PubMed ID: 16796699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benign prostatic hyperplasia and growth factors: mechanisms and hypotheses].
    Aumüller G
    Urologe A; 1992 May; 31(3):159-65. PubMed ID: 1377433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia.
    Cohen P; Peehl DM; Baker B; Liu F; Hintz RL; Rosenfeld RG
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1410-5. PubMed ID: 7525636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid.
    Sakamoto S; Yokoyama M; Zhang X; Prakash K; Nagao K; Hatanaka T; Getzenberg RH; Kakehi Y
    Endocrinology; 2004 Jun; 145(6):2929-40. PubMed ID: 14988385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia.
    Giri D; Ittmann M
    Am J Pathol; 2000 Jul; 157(1):249-55. PubMed ID: 10880394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
    Bonkhoff H; Remberger K
    Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia.
    Shapiro E; Becich MJ; Hartanto V; Lepor H
    J Urol; 1992 May; 147(5):1293-7. PubMed ID: 1373778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia.
    Cockett AT; di Sant'Agnese PA; Gopinath P; Schoen SR; Abrahamsson PA
    Urology; 1993 Nov; 42(5):512-9. PubMed ID: 7694415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
    Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
    Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the intraprostatic concentration of epidermal growth factor influence the variance of serum prostate specific antigen levels in patients with benign prostatic hyperplasia?
    Di Silverio F; Sciarra A; Monti S; Casale P; Seccareccia F
    J Urol; 1999 Jan; 161(1):128-32. PubMed ID: 10037384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic versus proliferative activities in human benign prostatic hyperplasia.
    Kyprianou N; Tu H; Jacobs SC
    Hum Pathol; 1996 Jul; 27(7):668-75. PubMed ID: 8698310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.